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ABSTRACT
established rheumatoid arthritis (RA), but a crucial
therapeutic goal is to delay/prevent progression of
undifferentiated arthritis (UA) or very early RA.
tion modulation in patients with UA or very early RA.
controlled, 2-year study, anti-cyclic citrullinated peptide
(CCP)2-positive patients with UA (not fulfilling the ACR
criteria for RA) and clinical synovitis of two or more joints
were randomised to abatacept (,10 mg/kg) or placebo
for 6 months; the study drug was then terminated. The
primary end point was development of RA (by ACR
criteria) at year 1. Patients were monitored by radio-
graphy, MRI, CCP2, rheumatoid factor and 28 joint count
Disease Activity Score (DAS28) over 2 years.
versus 16/24 (67%) placebo-treated patients developed
RA (difference (95% CI) 220.5% (247.4% to 7.8%)).
Adjusted mean changes from baseline to year 1 in
Genant-modified Sharp radiographic scores for abatacept-
treated versus placebo-treated patients, respectively,
were 0 versus 1.1 for total score, and 0 versus 0.9 for
erosion score. Mean changes from baseline to year 1 in
MRI erosion, osteitis and synovitis scores were 0, 0.2 and
0.2, respectively, versus 5.0, 6.7 and 2.3 in the abatacept
versus placebo groups. Safety was comparable between
groups; serious adverse events occurred in one patient
(3.6%) in each group.
early RA in some patients. An impact on radiographic and
MRI inhibition was seen, which was maintained for
6 months after treatment stopped. This suggests that it is
possible to alter the progression of RA by modulating
T-cell responses at a very early stage of disease.
The management of rheumatoid arthritis (RA)
improved dramatically following the introduction
of biological treatments
12and the increased focus
on early intensive treatment.
13 Despite these
advances, current treatment requires chronic use
of immunomodulatory agents, and prevention of
the progression of early disease remains an
important therapeutic goal.
Patients often present during an early undiffer-
entiated phase of arthritis, and one of the
challenges faced by rheumatologists (and clinical
trial designers) is the classification of these
patients. Seropositivity for anti-cyclic citrullinated
peptide (CCP) is a useful biomarker in these
patients, and indicates a high likelihood of progres-
sion to persistent and erosive disease.
4 Recent
advances in our understanding of the genetics of
RA susceptibility suggest that anti-CCP-positive
RA may actually represent a distinct disease
subset.
5 Given the strong predictive value of anti-
CCP, it is particularly relevant to examine patients
with early disease who are positive for this
autoantibody.
Two previous studies have investigated the
possibility of preventing disease progression in
groups with very early arthritis. In the PROMPT-
study (PRObable rheumatoid arthritis:
Methotrexate versus Placebo Treatment study),
6
methotrexate monotherapy delayed progression to
definite RA compared with placebo in a cohort of
patients with undifferentiated arthritis (UA) with
‘‘probable RA’’. Structural progression was slowed
relative to placebo; however, remission rates were
comparable between groups.
6 The impact of anti-
tumour necrosis factor therapy has recently been
examined in patients with poor prognosis UA.
7 In a
small cohort of patients, a short course of
infliximab treatment did not increase remission
rates or slow progression to definite RA compared
with placebo.
Several lines of evidence highlight a role for
T cells in the initiation of immunopathology,
suggesting that T-cell modulation may be an
effective strategy to prevent disease progression.
HLA molecules play an integral role in T-cell
activation, and shared epitope HLA alleles are
associated with the development of anti-CCP
antibodies
4 and anti-CCP-positive RA.
5 Biopsy
evidence demonstrates a predominance of acti-
vated T cells in active synovial joints,
89and RA-
like symptoms are induced in immunodeficient
mice following adoptive transfer of synovial T cells
from patients with RA.
10 11 There is evidence of a
specific therapeutic window for treatment; early
synovitis destined to develop into RA is charac-
terised by a distinct and transient synovial fluid
cytokine profile, including several T-cell cyto-
kines.
12 Abatacept modulates naı ¨ve T-cell activa-
tion and downstream cytokine production.
13 It is a
fully human, soluble fusion protein, which consists
of the extracellular domain of human cytotoxic
T-lymphocyte-associated antigen-4 (CTLA-4)
linked to the Fc portion of human immunoglobulin
Background Several agents provide treatment for
Objective To determine the impact of T-cell costimula-
Methods In this double-blind, phase II, placebo-
Results At year 1, 12/26 (46%) abatacept-treated
Conclusion Abatacept delayed progression of UA/very
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G1. The CTLA-4 portion of the molecule interrupts the CD80/ 
CD86:CD28 costimulatory signal, mimicking a native homoeo-
static mechanism of T-cell downregulation. In an experimental 
rat model, prophylactic administration of abatacept inhibited 
the onset of collagen-induced arthritis.14
Here, for the ﬁ  rst time, the ability of T-cell modulation to alter 
the course of disease progression in patients with UA or very 
early RA was tested by assessing the efﬁ  cacy of abatacept com-
pared with placebo in a patient population who did not fulﬁ  l the 
American College of Rheumatology (ACR) criteria for RA and 
who were anti-CCP2 positive.
PATIENTS AND METHODS
Patients
Eligible patients were aged ≥18 years, met at least one, but no 
more than three of the ACR criteria required for RA diagnosis,15 
had symptomatic clinical synovitis of at least two joints and did 
not meet the classiﬁ  cation criteria for any other rheumatic dis-
ease. Eligible patients were anti-CCP2 positive and had symptom 
duration (onset of UA to enrolment) of <18 months. Patients were 
excluded if they had received prior biological therapy or treatment 
with a disease-modifying antirheumatic drug. Corticosteroid treat-
ment was reduced to ≤10 mg prednisone (or equivalent) daily for 
28 days, and was stabilised for ≥25/28 days before study entry.
The ADJUST trial (Abatacept study to Determine the effec-
tiveness in preventing the development of rheumatoid arthritis 
in patients with Undifferentiated inﬂ  ammatory arthritis and to 
evaluate Safety and Tolerability) was approved by the appropri-
ate institutional review boards/independent ethics committees, 
and was carried out in accordance with the ethical principles of 
the Declaration of Helsinki. All patients gave written, informed 
consent.
Study protocol
This was an international, phase II, randomised, double-blind, 
placebo-controlled, exploratory study (ClinicalTrials.gov identi-
ﬁ  er: NCT0012444916). Patients from 21 sites in North America, 
Europe and South America were randomised 1:1 to receive 
abatacept at the approved dose of ∼10 mg/kg (according to 
weight range) or placebo for 6 months, after which treatment 
was terminated. Randomisation was stratiﬁ  ed for the presence 
of erosions. Abatacept was administered via a 30 min intra-
venous infusion on days 1, 15, 29, 57, 85, 113, 141 and 169. 
Follow-up assessments continued over 18 months. Patients, 
sites and the central laboratory conducting radiographic assess-
ment remained blinded to treatment assignments until the end 
of the 2-year study period.
Non-steroidal anti-inﬂ   ammatory drugs or stable low-dose 
oral corticosteroids (≤10 mg prednisone equivalent daily) were 
permitted, but disease-modifying antirheumatic drugs or biolog-
ical therapies were not. Patients who discontinued could receive 
the standard of care.
Primary end point
The primary end point was the proportion of patients who 
had developed RA deﬁ  ned by the 1987 ACR criteria15 at year 1. 
Patients who discontinued prematurely owing to lack of efﬁ  -
cacy were also considered as having developed RA, and were 
included in the primary end point.
Radiographic assessment
Radiographs of both hands/wrists and feet were taken at base-
line, month 6, and years 1 and 2 for patients who remained in 
the study. Digitised images were read at a central facility by 
two independent expert radiologists blinded to treatment allo-
cation, clinical response and chronological order of radiographs. 
The Genant-modiﬁ  ed Sharp scoring system was used to assess 
radiographs for changes in total score (TS), erosion score (ES) 
and joint-space narrowing (JSN) score.17 18
Magnetic resonance imaging assessment
Eligible patients from EU study sites were assessed using 
  gadolinium-enhanced magnetic resonance images of the hand/
wrist. Eligibility was determined by the site radiologist (contrain-
dications included claustrophobia, weight >250 lb (114 kg) and 
allergy or prior exposure (within 72 h) to a contrast agent). The hand/
wrist with the most prominent clinical synovitis was selected, and 
MRI evaluations were performed within 2 weeks before ﬁ  rst dose 
of study drug. Assessments were repeated at month 6 and year 1. 
Images were acquired with 1.5 Tesla (T) whole-body MRI scanners 
equipped with commercial imaging coils. The wrist and metacar-
pophalangeal joints were scanned separately. Scans included cor-
onal T1-weighted, three-dimensional gradient-echo, with spectral 
fat suppression (ﬂ  ip angle = 30°, repetition time = 33 ms, echo time 
= 12 ms, ﬁ  eld of view = 120 mm, matrix = 512 × 192, slice thick-
ness = 1.5 mm with no interslice gap) before and after intrave-
nous injection of gadolinium diethylenetriamine penta-acetic acid 
(0.1 mmol/kg) contrast material; and coronal fast short-tau inver-
sion recovery (inversion time = 150 ms, repetition time = 4500 ms, 
echo time = 30 ms, echo train length = 8; ﬁ  eld of view = 120 mm,
Table 1 Baseline demographics and clinical characteristics
Demographics/characteristics
Abatacept
(n=28)
Placebo
(n=28)
Age (years) 44.8 (10.9) 44.7 (12.1)
Gender, female, n (%) 20 (71.4) 20 (71.4)
Ethnicity, Caucasian, n (%) 25 (89.3) 23 (82.1)
Geographical region, n (%)
Europe 17 (60.7) 21 (75.0)
North America 6 (21.4) 5 (17.9)
South America 5 (17.9) 2 (7.1)
Disease duration (months) 8.8 (4.2) 7.1 (4.4)
Number of ACR criteria met, n (%)*
1 5 (17.9) 2 (7.1)
2 6 (21.4) 9 (32.1)
3 17 (60.7) 16 (57.1)
Number of joints with arthritis, n (%){
1 2 (7.1) 2 (7.1)
2–4 20 (71.4) 24 (85.7)
>5 5 (17.9) 2 (7.1)
Patients with erosions, n (%) 15 (53.6) 16 (57.1)
Radiographic erosion score 3.2 (3.5) 3.8 (3.3)
Radiographic JSN score 0.1 (0.4) 0.3 (0.9)
Radiographic total score 3.3 (3.6) 4.0 (3.6)
Physical function (HAQ-DI) 0.8 (0.6) 0.8 (0.6)
Levels of CRP (mg/dl) 1.12 (1.43) 1.07 (1.60)
Rheumatoid factor (% positive) 24 (85.7) 20 (71.4)
DAS28 (CRP) 3.6 (1.1) 3.4 (0.9)
Antirheumatic drugs
Corticosteroids (oral and/or injectable) 5 (17.9) 3 (10.7)
Corticosteroids (oral ,10 mg/day) 4 (14.3) 2 (7.1)
NSAIDs 22 (78.6) 25 (89.3)
Data are presented as mean (SD), unless otherwise specified.
*One patient in the placebo group was later discovered to have had rheumatoid
arthritis at baseline, and was withdrawn from the study; {one patient in the abatacept
group had no synovitis at baseline.
ACR, American College of Rheumatology; CRP, C-reactive protein; DAS28, 28 joint
count Disease Activity Score; HAQ-DI, Health Assessment Questionnaire-Disability
Index; JSN, joint space narrowing; NSAID, non-steroidal anti-inflammatory drug.
07_ar119016.indd   511 07_ar119016.indd   511 2/12/2010   6:12:01 PM 2/12/2010   6:12:01 PMExtended report
Ann Rheum Dis 2010;69:510–516. doi:10.1136/ard.2009.119016 512
matrix=2566192, slice thickness=3 mm). Magnetic reso-
nance images were scored for bone erosion, osteitis and
synovitis according to the RAMRIS method
19 by a single,
central radiologist blinded to treatment allocation, clinical
response and chronological order of the images.
Biomarker assessments
Serum samples were taken at baseline, month 6, and years 1 and
2; anti-CCP2 antibody and rheumatoid factor (RF) levels were
assessed by enzyme-linked immunosorbent assay.
Clinical efficacy assessment
A Kaplan–Meier analysis was performed on the time to
discontinuation owing to lack of efficacy. Lack of efficacy was
determined by the treating doctor, as recorded on the patient’s
case report form. Secondary clinical end points included 28 joint
count Disease Activity Score (DAS28) based on C-reactive
protein levels (with remission defined as DAS28 (CRP) ,2.6
16)
and swollen and tender joints, assessed using a 28-joint count.
Safety
Safety assessments were performed monthly for 6 months and
up to 56 days after the last dose of study drug, and then every
3 months up to year 2. Data presented here include the 6-month
treatment period plus 56 days of follow-up.
Sample size calculation
Sample size was based on the primary comparison between the
proportion of abatacept- and placebo-treated patients with RA
at year 1, and was not computed with the intention of having
adequate size to perform formal statistical tests. With a sample
size of 25 patients in each arm, the 95% two-sided confidence
interval (CI) half-width was 0.16 for the placebo group and 0.19
for the abatacept group. This power estimate assumed an
incidence of RA of 80% in the placebo group and 40% in the
abatacept group at year 1.
Data analyses
Owing to the exploratory nature of this study, analyses were
descriptive; formal statistical testing to generate p values for
comparisons between treatment groups was not planned or
conducted.
For the primary end point, patients who discontinued before
the 1-year assessment for reasons other than lack of efficacy
were excluded (predefined in the study protocol). Radiographic,
MRI, serology and clinical analyses were based on all patients
who remained in the trial and had data available at baseline and
the visit of interest (as observed). For radiographic data,
adjusted mean changes in TS, ES and JSN were based on an
analysis of the covariance model, with change from baseline as a
dependent variable and baseline value and treatment group as
covariates. For serum levels of anti-CCP2 autoantibodies and
Figure 1 Patient disposition over 2 years. AE, adverse event.
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RF, point estimates and 95% CIs were calculated. Exact CIs
were calculated using an ‘‘unconditional exact confidence
interval for the difference of proportions’’ procedure, from
StatXact (Cytel).
20 For the Kaplan–Meier analysis, an event was
defined as discontinuation due to lack of efficacy. The time to
event was the number of days between first study drug
administration and discontinuation (or the study completion
date). Patients who discontinued for reasons other than lack of
efficacy were censored at the time of discontinuation. For
DAS28 and joint counts, percentages were calculated based on
all patients who remained in the trial.
RESULTS
Baseline demographics and disease characteristics
A total of 56 patients were randomised and treated, and baseline
demographics and clinical characteristics were similar between
the groups (table 1). Overall, patients had a mean symptom
duration of 7.9 months, with a mean C-reactive protein level of
1.1 mg/dl. At baseline, 55.4% of patients had at least one
erosion; all patients were anti-CCP positive and 78.6% were RF
seropositive. Overall, 12.5, 26.8 and 58.9% patients met one,
two or three of the ACR criteria for RA at study entry,
respectively.
Patient disposition
Figure 1 shows the patient disposition. Over 6 months of
treatment, 6/28 (21.4%) patients in the abatacept group and
11/28 (39.3%) patients in the placebo group discontinued; of
these, three (10.7%) and eight (28.6%) were owing to lack of
efficacy, respectively. After treatment cessation, from month 6
to year 2, 15 (53.6%) and 13 (46.4%) patients randomised to the
original abatacept and placebo groups discontinued, respec-
tively; 11 (39.3%) and 12 (42.9%) of these were owing to lack of
efficacy. Seven (25.0%) and four (14.3%) patients randomised to
abatacept and placebo completed 2 years, respectively.
Development of rheumatoid arthritis by the ACR 1987 criteria
Over 1 year, six patients discontinued without developing RA
for reasons other than lack of efficacy, and were not included in
the primary efficacy analysis (prespecified). Therefore, 50/56
patients were evaluable; 26 and 24 were treated with abatacept
and placebo, respectively. At year 1 (6 months after treatment
discontinuation), 12/26 (46.2%) abatacept-treated and 16/24
(66.7%) placebo-treated patients had been diagnosed with RA as
defined by the ACR criteria.
4 The CIs for the difference between
the two groups included zero (difference (95% CI) 220.5%
(247.4% to 7.8%)); therefore, the primary end point for this
trial was not met.
Radiographic progression
Adjusted mean (standard error (SE)) changes from baseline to
month 6 in abatacept- versus placebo-treated patients were 0.15
(0.17) versus 0.46 (0.18) for TS, 0.14 (0.17) versus 0.45 (0.18) for
ES and 0 (0) versus 0.01 (0) for JSN scores, respectively (figs 2A,
B and C, respectively). Adjusted mean (SE) changes from
baseline to year 1 (6 months after treatment cessation) in
abatacept- versus placebo-treated patients were 0.01 (0.29)
versus 1.11 (0.36) for TS, 0.01 (0.20) versus 0.86 (0.25) for ES
and 0 (0.11) versus 0.26 (0.14) for JSN scores, respectively.
Estimates of difference (95% CI) for abatacept versus placebo at
year 1 were 21.10 (22.05 to 20.15) for TS, 20.84 (21.51 to
20.18) for ES and 20.26 (20.63 to 0.11) for JSN scores.
Confidence intervals did not include zero for either TS or ES.
While radiographic assessments continued up to year 2, small
patient numbers at this time point meant analysis of mean
changes from baseline were not meaningful after year 1.
Magnetic resonance imaging
Eleven abatacept- and 10 placebo-treated patients were eligible
for MRI assessments. Osteitis scores improved from baseline to
month 6 with abatacept (mean (SE) change 21.64 (1.48)), but
deterioration was observed with placebo (1.40 (1.59)). For
patients who remained in the trial at year 1, there was little
progression in osteitis score in the abatacept group (n=9;
change of 0.22 (0.49) from baseline). In the placebo group
Figure 2 Radiographic progression. Adjusted mean change from
baseline to month 6 and year 1 in (A) total score, (B) erosion score and
(C) joint-space narrowing score. Data are based on the intention-to-treat
population, using data available at the visit of interest (as observed).
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(n=6), however, osteitis scores worsened by 6.67 (4.22) from
baseline. MRI erosion and synovitis scores showed a similar
trend; at month 6, mean changes from baseline were 0.45 (0.37)
and 0.27 (0.56), respectively, in the abatacept group, and 1.20
(1.09) and 1.60 (1.23) in the placebo group. By year 1, mean
change from baseline in erosion and synovitis scores were 0
(0.17) and 0.22 (0.22), respectively, in the abatacept group
versus 5.00 (3.20) and 2.33 (1.61) in the placebo group.
Biomarkers
All patients were positive for anti-CCP2 antibodies at baseline.
The percentage of anti-CCP2-positive patients declined in the
abatacept group to 90.9% (20/22) at month 6, and 86.7%
(13/15) at year 1, while in the placebo group, all patients
remained positive at month 6 (19/19) and year 1 (10/10). These
data are consistent with results for changes in serum levels of
anti-CCP2 antibodies (table 2).
At baseline, 85.7 and 71.4% of patients in the abatacept and
placebo groups were positive for RF. The proportion of RF-
positive patients at month 6 and year 1 was 59.1% (13/22) and
73.3% (11/15), respectively, in the abatacept group, and 70.0%
(14/20) and 80.0% (8/10) in the placebo group. Table 2 shows
the mean changes in RF levels.
Clinical efficacy
Figure 3A shows a Kaplan–Meier curve of discontinuations due
to lack of efficacy over 2 years; the median times to
discontinuation were 507 and 344 days in the abatacept and
placebo groups, respectively. After 6 months, 71.4% (15/21)
versus 35.0% (7/20) of patients were in DAS28-defined
remission for the abatacept versus placebo groups, respectively
(fig 3B); at year 1 (following cessation of treatment for
6 months), the proportion of patients in DAS28-defined
remission was 47.4% (9/19) versus 38.5% (5/13). At 6 months,
the proportion of patients with zero swollen and tender joints
was 62.5% (15/24) versus 14.3% (3/21), for the abatacept versus
placebo groups, respectively; the proportion was 30.0% (6/20)
versus 14.3% (2/14) at year 1 (fig 3C).
Concomitant steroid use
During the 6-month treatment period, 17.9% of patients in each
group were receiving low-dose (,10 mg prednisone equivalent)
oral corticosteroids; in these patients, the mean (SD) dose was
4.8 (1.8) mg/day in the abatacept group and 6.0 (1.4) mg/day in
the placebo group. From month 6 to year 2, 17.9 and 25.0% of
patients in the abatacept and placebo groups were receiving
low-dose oral corticosteroids, at a mean (SD) dose of 4.3 (1.2)
and 6.0 (1.3) mg/day, respectively.
Safety
Table 3 summarises safety data over the 6-month treatment
period plus 56-day follow-up after last dose of the study drug.
Adverse events (AEs) were reported in 18 (64.3%) abatacept-
treated versus 20 (71.4%) placebo-treated patients. The most
frequently reported AEs (more than two patients in either
group) were diarrhoea, nasopharyngitis, urinary tract infection,
gastroenteritis, pharyngolaryngeal pain and headache. One
abatacept-treated patient (3.6%) discontinued owing to dys-
pnoea, and one placebo-treated patient (3.6%) discontinued
owing to thrombocytopenia. Serious AEs were reported in one
patient (3.6%) in each group. One was a basal cell carcinoma
reported in a 74-year-old abatacept-treated patient (the only
malignancy reported). The other was a case of lumbar sciatica in
the placebo group. There were no reports of treatment-related
serious AEs or discontinuations due to serious AEs. Infections
were reported in 10 (35.7%) abatacept-treated and 11 (39.3%)
placebo-treated patients. The most frequently reported infec-
tions (.10% overall) were nasopharyngitis (three abatacept vs
two placebo patients), urinary tract infection (two abatacept vs
three placebo patients) and gastroenteritis (no abatacept vs
three placebo patients). Acute (within 1 h) infusional reaction
was reported in one patient (3.6%) in each group, and peri-
(within 24 h) infusional reactions were reported in two (7.1%)
and three (10.7%) patients in the abatacept and placebo groups,
respectively. No deaths occurred in either group.
DISCUSSION
This exploratory study examined the impact of abatacept in a
subset of poor prognosis patients with UA or very early RA.
Although abatacept monotherapy did not prevent development
of RA by the ACR 1987 criteria at 1 year (and therefore the
primary end point was not met), it impacted radiographic and
MRI progression for >6 months after the cessation of treat-
ment. A reduction in the level of anti-CCP antibodies was seen
after 6 months that was still evident at year 1. This is the first
study to demonstrate the efficacy of T-cell costimulation
modulation with abatacept in a population of patients with
UA or very early RA. The efficacy benefits observed with
abatacept monotherapy were coupled with acceptable safety.
Table 2 Mean changes in serum anti-cyclic citrullinated peptide (CCP) and rheumatoid factor (RF) levels
Abatacept Placebo
Serum anti-CCP (U/ml)
Baseline (month 6 analysis)* 227.6 (289.8) 145.5 (98.2)
Month 6* 133.1 (198.2) 161.9 (155.3)
Mean change from baseline to month 6 (95% CI)* 294.5 (2156 to 233.0) 16.3 (228.8 to 61.5)
Baseline (year 1 analysis){ 270.0 (325.4) 212.9 (131.3)
Year 1{ 263.5 (430.0) 362.4 (314.2)
Mean change from baseline to year 1 (95% CI){ 26.5 (2110 to 97.4) 149.5 (3.8 to 295.1)
Serum RF (U/ml)
Baseline (month 6 analysis){ 167.5 (249.8) 63.5 (92.0)
Month 6{ 42.4 (46.3) 61.5 (82.9)
Mean change from baseline to month 6 (95% CI){ 2125 (2218 to 232.1) 22.0 (215.4 to 11.5)
Baseline (year 1 analysis)1 137.0 (212.1) 54.9 (51.5)
Year 11 96.3 (109.7) 47.1 (53.9)
Mean change from baseline to year 1 (95% CI)1 240.7 (2133.0 to 51.3) 27.8 (235.2 to 19.6)
*n=21 and 19; {n=14 and 10; {n=22 and 20; 1n=15 and 10, for abatacept and placebo, respectively.
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The reduction in anti-CCP2 levels observed after 6 months of
abatacept treatment is suggestive of an effect on the underlying
autoimmune process. Anti-CCP2 antibodies are highly predic-
tive of the development of RA and, although not formally
validated to assess disease activity, reductions in anti-CCP2
have been linked to improvements in clinical status in patients
given biological treatments.
21 22 This is consistent with the effect
on radiological damage that persisted beyond cessation of active
treatment, which suggests that the impact of abatacept may be
most substantial at the primary site of disease, affecting early
synovitis. This is further supported by the inhibition of osteitis,
the presence of which is strongly predictive of subsequent
radiographic progression in patients with early RA.
23 These data
support the concept of a therapeutic window, during which the
course of disease may be altered,
12 and several lines of evidence
indicate a key role for abatacept in the inhibition of structural
damage. Synovial biopsy data from abatacept-treated patients
with RA are consistent with a regulatory role of abatacept in
osteoclast differentiation and bone resorption,
24 and recent
data
25 have demonstrated that abatacept can directly inhibit the
differentiation of osteoclast precursors, suggesting a further
mechanism for the inhibition of erosion observed here.
Based on a Kaplan–Meier analysis, the cumulative rate of
progression to RA (defined by the ACR 1987 criteria
15) was
lower in the abatacept than the placebo group throughout the
2-year study. Rates of DAS28-defined remission were more than
twofold greater in the abatacept than placebo groups at month
6. Although the DAS28 has been validated in patients with
RA,
26 it has not been validated in patients with UA, so swollen
and tender joint counts may be a more clinically relevant
assessment in these patients; the proportion of patients with
zero swollen and tender joints was fivefold greater in the
abatacept versus placebo groups at month 6. For both of these
efficacy measures, rates remained higher in the original
abatacept versus placebo group at year 1, despite treatment
cessation.
Although the patients in this trial did not have RA as defined
by the ACR 1987 criteria, approximately half already exhibited
evidence of erosions at baseline, and it is likely that a significant
proportion had early RA. At the time this study was designed
(2004), a diagnosis of UA required the presence of inflammatory
arthritis in patients not satisfying the ACR 1987 criteria for RA
15
or any other rheumatic disease. However, owing to the low
discriminative ability of the ACR criteria in patients with
recent-onset arthritis,
27 it is generally accepted that patients
may have early RA even if they do not meet the ACR 1987
criteria. Consequently, there is currently uncertainty around the
terminology and classification of this group of patients, and the
ACR criteria for early disease are currently under revision. It
should also be noted that although the ACR criteria are
commonly used in RA clinical trials, they do not represent a
definitive diagnostic tool to assess the development of RA; it is
likely that a number of patients included in this study may have
actually been diagnosed with RA in clinical practice. Therefore,
the ‘‘window of opportunity’’ for early treatment may have
already passed for some patients.
Figure 3 Clinical efficacy. (A) Kaplan–Meier plot showing the
proportion of patients who discontinued owing to lack of efficacy over 2
years. One patient was diagnosed with RA at baseline and was excluded
from the analyses; *Patients who discontinued for reasons other than
lack of efficacy were censored at the time of discontinuation.
(B) Proportion of patients achieving DAS28-defined remission over 2
years. (C) Proportion of patients with zero swollen and tender joints over
2 years. DAS28, 28 joint count Disease Activity Score.
Table 3 Summary of safety over the 6-month treatment period*
Abatacept
(n=28)
Placebo
(n=28)
AEs, n (%) 18 (64.3) 20 (71.4)
Discontinuations due to AEs 1 (3.6) 1 (3.6)
Serious AEs, n (%) 1 (3.6) 1 (3.6)
Discontinuations due serious AEs 0 0
Infections, n (%) 10 (35.7) 11 (39.3)
Malignancies, n (%) 1 (3.6) 0
Deaths, n (%) 0 0
*Including a follow-up period of up to 56 days after the last dose of study drug.
AE, adverse event.
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Some limitations must be considered when interpreting these
findings. In this exploratory trial, patient numbers were low
and formal statistical hypothesis testing was not performed.
Although the primary end point of the trial was not met, it is
possible that significance might have been observed in a larger
sample with greater statistical power. Over-time analysis of the
primary end point (RA defined by the ACR criteria
15) was not
possible owing to the requirement for radiographic assessment.
Although discontinuation due to lack of efficacy allowed
estimation of time to RA development, ‘‘lack of efficacy’’ was
defined by the treating doctor and so may not have been
completely aligned with development of RA according to the
ACR criteria.
15 Finally, the small number of patients remaining
in the study over time meant that analysis of efficacy data was
not meaningful in the second year.
In summary, abatacept reduced anti-CCP antibody levels and
maintained the inhibition of radiographic and MRI progression
for >6 months after treatment cessation in patients with UA or
very early RA. Studies in larger patient populations will help to
confirm these findings. These data suggest that it is possible to
alter the progression of RA by modulating T-cell responses at a
very early stage in disease.
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